Literature DB >> 20356854

PINK1-linked parkinsonism is associated with Lewy body pathology.

Lluís Samaranch1, Oswaldo Lorenzo-Betancor, José M Arbelo, Isidre Ferrer, Elena Lorenzo, Jaione Irigoyen, Maria A Pastor, Carmen Marrero, Concepción Isla, Joanna Herrera-Henriquez, Pau Pastor.   

Abstract

Phosphatase and tensin homolog-induced putative kinase 1 gene mutations have been associated with autosomal recessive early-onset Parkinson's disease. To date, no neuropathological reports have been published from patients with Parkinson's disease with both phosphatase and tensin homolog-induced putative kinase 1 gene copies mutated. We analysed the coding region of phosphatase and tensin homolog-induced putative kinase 1 gene in a large Spanish family with six members with parkinsonism. The phenotype was characterized by an early-onset (mean: 31.6, standard deviation: 9.6 years, range: 14-45 years), slowly progressive levodopa-responsive parkinsonism, initial gait impairment and psychiatric symptoms. We identified two segregating pathogenic phosphatase and tensin homolog-induced putative kinase 1 mutations that were either in homozygous or heterozygous compound state in all affected family members. We found an exon 7 deletion (g.16089_16383del293; c.1252_1488del) and a novel+1U1-dependent 5' splice-site mutation in exon 7 (g.16378G>A; c.1488+1G>A). Leukocyte-derived messenger RNA analysis showed that both mutations caused exon 7 skipping and c.1488+1G>A also lead to an in-frame transcript with a 33 base-pair deletion (p.L485_R497del) resulting from activation of a 5' cryptic exon 7 splice site. Single photon emission computed tomography quantification of striatal dopamine transporter binding (123I-Ioflupane) revealed a posterior-anterior gradient similar to that of idiopathic Parkinson's disease, but there was no correlation between striatal reduced uptake and disease duration. Post-mortem neuropathological examination of an early-onset Parkinson's disease carrier of two heterozygous compound phosphatase and tensin homolog-induced putative kinase 1 mutations showed neuronal loss in the substantia nigra pars compacta, Lewy bodies and aberrant neurites in the reticular nuclei of the brainstem, substantia nigra pars compacta and Meynert nucleus, but the locus ceruleus and the amygdala were spared. This is the first neuropathological report of the brain from an early-onset phosphatase and tensin homolog-induced putative kinase 1-linked parkinsonism showing that mutated phosphatase and tensin homolog-induced putative kinase 1 protein induces Lewy body pathology. Unbalanced preservation of the locus ceruleus may well play a role in the slow evolution of motor symptoms and, probably, in the psychiatric symptoms often encountered in Parkinson's disease associated with phosphatase and tensin homolog-induced putative kinase 1 mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356854     DOI: 10.1093/brain/awq051

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  83 in total

1.  Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease.

Authors:  R K Dagda; A M Gusdon; I Pien; S Strack; S Green; C Li; B Van Houten; S J Cherra; C T Chu
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Authors:  Nicholas T Hertz; Amandine Berthet; Martin L Sos; Kurt S Thorn; Al L Burlingame; Ken Nakamura; Kevan M Shokat
Journal:  Cell       Date:  2013-08-15       Impact factor: 41.582

Review 4.  Parkin and PINK1 functions in oxidative stress and neurodegeneration.

Authors:  Sandeep K Barodia; Rose B Creed; Matthew S Goldberg
Journal:  Brain Res Bull       Date:  2016-12-23       Impact factor: 4.077

Review 5.  CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Authors:  Fatemeh Safari; Gholamreza Hatam; Abbas Behzad Behbahani; Vahid Rezaei; Mazyar Barekati-Mowahed; Peyman Petramfar; Farzaneh Khademi
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

Review 6.  A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease.

Authors:  Charleen T Chu
Journal:  Hum Mol Genet       Date:  2010-04-12       Impact factor: 6.150

Review 7.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 9.  Genetic analysis of pathways to Parkinson disease.

Authors:  John Hardy
Journal:  Neuron       Date:  2010-10-21       Impact factor: 17.173

Review 10.  RNA mis-splicing in disease.

Authors:  Marina M Scotti; Maurice S Swanson
Journal:  Nat Rev Genet       Date:  2015-11-23       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.